Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Inclusion Criteria: * Male or female 40-75 years of age, inclusive; * History of physician-diagnosed (e.g., by clinical history, \>15-pack year history of smoking, physical examination, and spirometry) COPD treated for ≥ 3 months prior to Visit 1 Pre-Screening; * FEV1 ≥ 30% and \< 80% predicted and FEV1/FVC ratio \< 0.7 at Visit 1 Pre-Screening and Visit 2 Screening; * Negative urine pregnancy test for all females unless the subject is post-menopausal (≥ 24 months of spontaneous amenorrhea) or surgically sterile (hysterectomy, bilateral ovariectomy or bilateral tubal ligation); * Negative urine drug screen for cocaine, phencyclidine (PCP), methamphetamine; * Negative alcohol breath test; * Electrocardiogram (ECG) without serious abnormality and with QTcB and QTcF \< 460 milliseconds (msec); * Ability to wash-out of concomitant LABA and Theophylline, if ongoing, for 7-8 days (i.e., Visit 2 Screening through 5-Day Treatment Period). * Legally effective written informed consent obtained prior to starting any study procedures. * Subject willing and able to comply with the protocol and procedures, as judged by Investigator. Exclusion Criteria: * Sustained release methylxanthine (e.g. Theophylline) or long acting beta agonists ≤ 48 hours prior to treatment start (Day 1); * Acute exacerbation of COPD requiring emergency treatment ≤ 30 days of screening or hospitalization ≤ 60 days of Visit 2 Screening; * Antibiotic therapy for respiratory infection ≤ 15 days of Visit 2 Screening; * Presence of active respiratory disease such as pneumonia and acute exacerbation of chronic bronchitis; * Hypokalemia defined as a potassium level \<3.0 mmol/L at Visit 2 Screening. note: Subjects \<3.0 mmol/L may be re-screened at Visit 2 Screening after receiving potassium replacement therapy; * Significant clinical laboratory abnormality that, in the opinion of the Investigator, may put the subject at risk; * Significant renal, hepatic, endocrine, neurologic or other systemic disease that, in the opinion of the Investigator, may put the subject at undue risk; * Uncontrolled hypertension (defined as a blood pressure ≥ 170/100 mm Hg at Visit 1 Pre-Screening) and/or uncontrolled angina, uncontrolled diabetes, uncontrolled congestive heart failure (CHF), uncontrolled serious arrhythmia; * Myocardial infarction within 6 months of treatment start; * Pregnant or lactating females; * Participation in another clinical study with an investigational drug within 30 days of Visit 1 Pre-Screening; * Patients with home oxygen requirements. * A known allergy to excipients of the MN-221 drug product; * A known allergy to other beta agonists; * Currently on medication/s that are recognized to have risk of Torsades de Pointes